Pedro L Ferreira1, Isabel Luzeiro2, Margarida Lopes3, André Jorge4, Bruno Silva4, Lara Ferreira5. 1. Centre for Health Studies and Research of University of Coimbra/Centre for Innovative Biomedicine and Biotechnology, Faculty of Economics of University of Coimbra, Coimbra, Portugal. pedrof@fe.uc.pt. 2. Neurology Department of Coimbra University Hospital Centre, Faculty of Medicine of University of Coimbra, Coimbra, Portugal. 3. Neurology Department of Braga Hospital, Braga, Portugal. 4. Neurology Department of Coimbra University Hospital Centre, Coimbra, Portugal. 5. Centre for Health Studies and Research of University of Coimbra/Centre for Innovative Biomedicine and Biotechnology, University of Algarve, School of Management, Hospitality and Tourism, Faro, Portugal.
Abstract
BACKGROUND: Migraine Disability Assessment Scale (MIDAS) is a useful tool to measure headache-related disability. Modified MIDAS with 4-week recall period reduces recall bias and improves accuracy of the results. This study aimed at validating mMIDAS in Portuguese. METHODS: Studied population consisted of adult migraine patients attending a headache outpatient clinic. Reliability was assessed by internal consistency and reproducibility in a 3-week test-retest. Content validity was evaluated by two expert panels. Construct validity was tested by comparing mMIDAS-P index in socioeconomic and clinical patient groups and scale unidimensionality was evidenced by factor analysis. Criterion validity was tested using EQ-5D-5L and HADS. RESULTS: Ninety-two patients, 88% female, mean age of 44 years, participated. They had, in average, 9.7 headache days in previous month, pain averaging 7.5/10. About 69.9% were on a migraine prophylactic treatment, and 42.4% had severe disability; 29.4 and 13.0% showed, respectively, moderate/severe anxiety and depression. Content validity showed that mMIDAS-P is simple and clinically useful. It did not show to be determined by patient's sociodemographic characteristics and it was correlated with depression scale and EQ-5D-5L. Test-retest demonstrated high reproductive reliability and good internal consistency. CONCLUSION: mMIDAS-P is valid and reliable. We strongly recommend it for clinical and research use.
BACKGROUND:Migraine Disability Assessment Scale (MIDAS) is a useful tool to measure headache-related disability. Modified MIDAS with 4-week recall period reduces recall bias and improves accuracy of the results. This study aimed at validating mMIDAS in Portuguese. METHODS: Studied population consisted of adult migrainepatients attending a headacheoutpatient clinic. Reliability was assessed by internal consistency and reproducibility in a 3-week test-retest. Content validity was evaluated by two expert panels. Construct validity was tested by comparing mMIDAS-P index in socioeconomic and clinical patient groups and scale unidimensionality was evidenced by factor analysis. Criterion validity was tested using EQ-5D-5L and HADS. RESULTS: Ninety-two patients, 88% female, mean age of 44 years, participated. They had, in average, 9.7 headache days in previous month, pain averaging 7.5/10. About 69.9% were on a migraine prophylactic treatment, and 42.4% hadsevere disability; 29.4 and 13.0% showed, respectively, moderate/severe anxiety and depression. Content validity showed that mMIDAS-P is simple and clinically useful. It did not show to be determined by patient's sociodemographic characteristics and it was correlated with depression scale and EQ-5D-5L. Test-retest demonstrated high reproductive reliability and good internal consistency. CONCLUSION:mMIDAS-P is valid and reliable. We strongly recommend it for clinical and research use.
Authors: Pedro L Ferreira; Patrícia Antunes; Lara N Ferreira; Luís N Pereira; Juan M Ramos-Goñi Journal: Qual Life Res Date: 2019-06-14 Impact factor: 4.147
Authors: Thomas Benz; Susanne Lehmann; Andreas R Gantenbein; Peter S Sandor; Walter F Stewart; Achim Elfering; André G Aeschlimann; Felix Angst Journal: Health Qual Life Outcomes Date: 2018-03-09 Impact factor: 3.186